Clinical and regulatory intelligence for RUNX1 Familial Platelet Disorder with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

Safety →

Relevant companies

No related entities indexed yet.

Recent signals(1)

ClinicalAugust 2, 2026

Safety and Feasibility Study of CD34+ Stem Cells in RUNX1 Familial Platelet Disorder

A study is underway to assess the safety and feasibility of mobilizing and collecting autologous CD34+ hematopoietic stem cells in patients with RUNX1 familial platelet disorder.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Hematology →

RUNX1 Familial Platelet Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.